Andrew Jensen

Andrew Jensen is an associate in Goodwin’s Antitrust and Competition practice. He advises clients on antitrust and competition issues, including merger reviews, compliance, government antitrust investigations, antitrust litigation, and other regulatory issues. He has significant experience in premerger counseling, including compliance with Hart-Scott-Rodino premerger requirements, and has also successfully guided clients through investigations before the DOJ and FTC. Andrew has experience counseling clients across a wide range of industries, including healthcare, pharmaceuticals, financial services, consumer products, retail, manufacturing, among others.

Andrew is committed to pro bono service, including successfully representing clients in asylum merits hearings, in collaboration with Catholic Charities Immigration Legal Services, Community Legal Services in East Palo Alto (CLSEPA), and Lawyers for Good Government.

Andrew’s representative experience includes advising:

• iRobot in its proposed acquisition by Amazon
• Inversago Pharma in its acquisition by Novo Nordisk, worth up to $1.08 billion
• PPD in its $17.4 billion acquisition by Thermo Fisher Scientific*
• Change Healthcare’s $13.8 billion acquisition by Optum*
• Hellman & Friedman in its acquisition of The NPD Group*
• BMC Stock Holdings in its $5.5 billion merger with Builders FirstSource*
• Waystar in its acquisition of eSolutions*

*Denotes experience prior to joining Goodwin.